18 December 2017 in Clinical Cardiology
12 June 2020 in Clinical Cardiology
SARS‐CoV‐2, the cause of the COVID‐19 pandemic has significantly impacted cardiovascular healthcare. Patients with pre‐existing cardiovascular disease are at higher risk of morbidity and mortality. The virus may affect the heart directly and indirectly with clinical syndromes of acute myocardial injury, myocarditis, acute coronary syndromes, heart failure, arrhythmias, and venous thromboembolism. Some therapeutics under investigation for COVID‐19 may also have adverse cardiac effects. The involvement of the RAAS system in viral entry makes it pertinent to consider the effects of medications that modulate the system. Comprehensive knowledge of peculiar cardiovascular manifestations of COVID‐19 and the role of RAAS in the prognosis of COVID‐19 disease is needed for optimal patient management.
9 July 2018 in The Journal of Clinical Hypertension
SPRINT (Systolic Blood Pressure Intervention Trial) highlighted the benefits of intensive targeted antihypertensive therapy but resulted in higher rates of treatment‐related adverse events. Blood pressure (BP) variability has emerged as a significant predictor of outcomes over and above levels of BP. Using the SPRINT data set, we aimed to determine the relationship of BP variability with cardiovascular outcomes and side effects of antihypertensive therapy. The analyses included all participants randomized in SPRINT who reached the target systolic BP (SBP) for their respective groups (intensive < 120 mm Hg; standard < 140 mm Hg). Coefficients of variation (CV) for SBP, diastolic BP (DBP), and PP for each patient characterized variability. Student t test was used to compare treatment arms for each CV metric. Cox proportional hazards regression was used to identify independent predictors of the SPRINT primary outcome and adverse events. P < .15 on univariate analysis was required to enter the model and P < .05 to remain in it. A total of 8884 patients (4561 standard group; 4323 intensive group) met inclusion criteria. DBP CV differed between the groups (9.12 ± 3.20 standard group; 9.47 ± 3.49 intensive group [P < .0001]). DBP CV predicted a greater hazard for the primary outcome (hazard ratio [HR], 1.14) in the overall model as well as separate analyses by treatment arms (standard group HR, 1.15; intensive group HR, 1.19), each P < .0001. DBP CV also independently predicted a greater hazard for acute kidney injury (HR, 1.12) and hypotensive events (HR, 1.12). Visit‐to‐visit DBP variability independently predicted worse cardiovascular outcomes and hypoperfusion‐related adverse events in SPRINT.
1 January 2016 in Progress in Cardiovascular Diseases
3 September 2013 in Perspectives in Public Health
Developing countries face a dual challenge of both communicable and non-communicable disease – 80% of deaths from cardiovascular disease occur in low and middle-income countries. Hypertension ranks highest as an attributable cause of mortality in both developed and developing countries. The prevalence of hypertension is rising rapidly in Nigeria, from 11% two decades ago to about 30% in recent times. This review explores salt reduction in the diet at the population-wide level as a means of reducing the burden of hypertension in Nigeria. The evidence behind this strategy is explored, methods of how this goal was achieved in other countries are investigated and recommendations on how it could be accomplished in the Nigerian context are considered. There are suggestions that if salt reductions are effectively implemented on a population-wide basis, it will have an impact on morbidity and mortality as large as that which the provision of drains and safe water had in the 19th century.
16 March 2018 in Journal of Artificial Organs